Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Helen Torley, President and CEO of Halozyme Therapeutics , Inc. (NASDAQ:HALO), a $7.1 billion biotechnology company with a perfect Piotroski Score of 9 according to InvestingPro, sold a total of 40,200 shares of common stock between July 8 and July 10, 2025. The sales, conducted under a pre-arranged 10b5-1 trading plan, fetched prices ranging from $54.483 to $57.617, totaling approximately $3,387,517.
The sales were executed following the exercise of options to purchase 60,000 shares of Halozyme common stock at a price of $8.11 per share, for a total of $486,600. These options were exercised on July 8, 9, and 10, 2025. The company currently trades at a P/E ratio of 15, which InvestingPro analysis suggests is attractive relative to its near-term earnings growth potential.
Following these transactions, Torley directly owns 733,719 shares of Halozyme Therapeutics. The company’s strong financial health is reflected in its impressive 76% gross profit margin and management’s active share buyback program. For deeper insights into Halozyme’s valuation and 12 additional ProTips, visit InvestingPro.
In other recent news, Halozyme Therapeutics has reported several notable developments. The company announced that argenx received European Commission approval for VYVGART, a subcutaneous injection developed using Halozyme’s ENHANZE technology, for treating chronic inflammatory demyelinating polyneuropathy. This approval extends to all European Union member states and is based on the ADHERE clinical trial results. Additionally, Halozyme has been added to the U.S. large-cap Russell 1000 Index, reflecting its market capitalization and performance.
Goldman Sachs resumed coverage of Halozyme with a Neutral rating, citing uncertainties regarding upcoming drug pricing negotiations with the Centers for Medicare and Medicaid Services. Meanwhile, TD Cowen analysts maintained a Buy rating, suggesting the stock remains undervalued despite potential impacts from the Inflation Reduction Act. H.C. Wainwright also reiterated a Buy rating following the European Commission’s approval of the subcutaneous version of Bristol-Myers Squibb (NYSE:BMY)’s Opdivo, which uses Halozyme’s technology. These developments indicate ongoing interest and activity surrounding Halozyme’s product offerings and strategic positioning in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.